Earth Science Tech, Inc. (OTC: ETST), a strategic holding company focused on a diversified portfolio, has announced the acquisition of Zoolzy LLC, a Doral, Florida-based wholesale distributor of active pharmaceutical ingredients (APIs) and finished FDA-approved prescription products. The acquisition is expected to integrate Zoolzy into ETST’s supply chain, enabling its compounding pharmacies to procure APIs at competitive wholesale pricing, which the company says could increase overall profit margins.
Zoolzy operates from a 3,684-square-foot facility and provides immediate procurement access to common veterinary medications. This acquisition broadens ETST’s access to novel APIs for custom compounding, which is critical for its compounding pharmacy operations. By securing a direct supply line, ETST reduces reliance on third-party distributors, potentially lowering costs and improving efficiency.
The move is part of ETST’s broader strategy to build a vertically integrated healthcare platform. The company’s principal operating strategy is to combine compounding pharmacy operations, telemedicine platforms, clinical support, and direct-to-patient fulfillment. The acquisition of Zoolzy strengthens the supply chain component, which is essential for the seamless integration of patient care from consultation to fulfillment.
ETST plans to leverage the new supply line to expand into the animal health market with unique, flavored, and easy-to-administer veterinary therapeutics. This initiative is led by members of its management team who have experience and established networks in the exotic wildlife space. This expansion into veterinary medicine represents a significant diversification for the company, tapping into a growing market for pet and animal health products.
The acquisition is expected to have several implications for ETST and the broader pharmaceutical supply chain. By securing a direct distributor of APIs, ETST can potentially reduce costs, improve supply chain resilience, and gain access to a wider range of ingredients for custom compounding. This could lead to higher profit margins and more competitive pricing for its pharmacy services.
Furthermore, the move into veterinary therapeutics aligns with the increasing demand for specialized animal health products. With the management team’s expertise in exotic wildlife, ETST is well-positioned to introduce innovative products that address the unique needs of veterinarians and pet owners. This could open new revenue streams and strengthen the company’s market position.
The acquisition also underscores the importance of vertical integration in the healthcare industry. By controlling the supply chain, companies like ETST can ensure quality, reduce costs, and respond more quickly to market demands. This strategy is particularly relevant for compounding pharmacies, which rely on timely access to APIs to create customized medications.
Investors and industry observers will be watching how ETST integrates Zoolzy and whether it can successfully execute its expansion into the veterinary market. The company’s ability to leverage this acquisition will be key to its future growth and profitability.
For more information, visit the full press release at https://ibn.fm/nHFqQ. The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST.
